Nautilus Biotechnology (NASDAQ:NAUT) Stock Price Up 0.8% – Here’s What Happened

Nautilus Biotechnology, Inc. (NASDAQ:NAUT)’s share price shot up 0.8% on Friday . The company traded as high as $2.50 and last traded at $2.40. 108,352 shares were traded during trading, an increase of 37% from the average session volume of 79,021 shares. The stock had previously closed at $2.38.

Nautilus Biotechnology Price Performance

The company has a market cap of $301.34 million, a P/E ratio of -4.29 and a beta of 1.23. The stock’s 50-day moving average is $2.70 and its two-hundred day moving average is $2.61.

Nautilus Biotechnology (NASDAQ:NAUT) last released its quarterly earnings results on Tuesday, October 29th. The company reported ($0.13) earnings per share for the quarter, beating the consensus estimate of ($0.17) by $0.04. During the same period in the prior year, the firm earned ($0.13) EPS. On average, analysts predict that Nautilus Biotechnology, Inc. will post -0.57 EPS for the current year.

Insider Buying and Selling

In other Nautilus Biotechnology news, VP Mary E. Godwin sold 47,031 shares of the company’s stock in a transaction dated Monday, September 23rd. The stock was sold at an average price of $2.87, for a total value of $134,978.97. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 40.50% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of NAUT. Price T Rowe Associates Inc. MD lifted its position in shares of Nautilus Biotechnology by 35.8% in the first quarter. Price T Rowe Associates Inc. MD now owns 16,078 shares of the company’s stock valued at $48,000 after acquiring an additional 4,239 shares in the last quarter. SG Americas Securities LLC bought a new stake in Nautilus Biotechnology during the 3rd quarter valued at approximately $50,000. The Manufacturers Life Insurance Company purchased a new position in Nautilus Biotechnology in the 3rd quarter worth approximately $67,000. China Universal Asset Management Co. Ltd. boosted its stake in Nautilus Biotechnology by 63.9% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 24,121 shares of the company’s stock worth $69,000 after purchasing an additional 9,404 shares during the period. Finally, MetLife Investment Management LLC purchased a new stake in Nautilus Biotechnology during the 3rd quarter valued at approximately $87,000. Institutional investors own 50.71% of the company’s stock.

About Nautilus Biotechnology

Nautilus Biotechnology, Inc, a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis.